Recombinant Human CTNNB1,GST-tagged

• Cat.No.: CTNNB1-1441H
• Product Overview: Recombinant full-length human Catenin beta was expressed by baculovirus inSf9 insect cellsusing an N-terminal GST tag. MW = 115kDa.

Specification

• Cat. No.: CTNNB1-1441H
• Description: β-catenins are cytoplasmic proteins that are ubiquitously expressed. These proteins associate with E-cadherin at cellular junctions. β-catenin interacts with TCF and LEF transcription factors and is an essential member of the Wingless-Wnt signal transduction pathway. The adenomatous polyposis coli (APC) tumor-suppressor protein, together with Axin and GSK3β, form a Wnt-regulated signaling complex that mediates phosphorylation-dependent degradation of β-catenin by the proteasome. APC and Siah-1 mediate a novel β-catenin degradation pathway linking p53 activation to cell cycle control. Activating mutations in the human β-catenin gene have been found in human colon cancer and melanomas.
• Source: Sf9 insect cells using baculovirus.
• Sequence: Full-length.
• Applications: Western Blot.
• Storage And Stability: Store product at -70℃. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

Gene Information

• Gene Name: CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa [ Homo sapiens ]
• Synonyms: CTNNB1; catenin (cadherin-associated protein), beta 1, 88kDa; CTNNB; FLJ25606; FLJ37923; DKFZp686D02253; beta-catenin; Catenin beta-1; Beta-catenin
• Gene ID: 1499
• mRNA Refseq: NM_001098209
• Protein Refseq: NP_001091679
• MIM: 116806
• UniProt ID: P35222
• Chromosome Location: 3p21
• Pathway: Adherens junction; Arrhythmogenic right ventricular cardiomyopathy (ARVC); Basal cell carcinoma; Colorectal cancer; Endometrial cancer; Focal adhesion; Leukocyte transendothelial migration; Melanogenesis; Pathogenic Escherichia coli infection; Pathways in cancer; Prostate cancer; Thyroid cancer; Tight junction; Wnt signaling pathway; Apoptosis; Cell-cell adhesion systems; Signaling by Wnt
• Function: I-SMAD binding; alpha-catenin binding; androgen receptor binding; cadherin binding; chromatin binding; double-stranded DNA binding; kinase binding; promoter binding; protein C-terminus binding; protein phosphatase binding; signal transducer activity; transcription coactivator activity; transcription factor activity; transcription factor binding

Reviews

03/27/2023

Not only does it provide reliable and consistent results due to its high quality and purity, but it also holds significant value in understanding cellular processes and disease mechanisms.

07/28/2017

the CTNNB1 protein offers numerous advantages in trials and research experiments.

06/24/2016

This commitment to excellence ensures that researchers are provided with the most advanced and reliable tools for their investigations.

Q&As

Is the CTNNB1 protein involved in the progression of pancreatic cancer?

Yes, CTNNB1 is implicated in the development and progression of pancreatic cancer, with its dysregulated activity contributing to tumor growth, invasion, and metastasis.

How is the CTNNB1 protein associated with hepatocellular carcinoma (HCC)?

Mutations in the CTNNB1 gene lead to the stabilization and accumulation of β-catenin, contributing to the development of HCC, making it a potential biomarker for the diagnosis and prognosis of HCC.

How is the CTNNB1 protein linked to the prognosis of gastric cancer patients?

Studies have shown that CTNNB1 expression levels can serve as an independent prognostic factor in gastric cancer, with high CTNNB1 expression correlating with poor patient outcomes.

Are there any targeted therapies specifically aimed at CTNNB1 in cancer treatment?

While there are no direct CTNNB1-targeted therapies available, various drugs targeting the Wnt signaling pathway are being developed and tested, which indirectly impact CTNNB1 activity in cancer cells.

How is the expression of CTNNB1 in breast cancer cells associated with patient survival?

High expression levels of CTNNB1 in breast cancer cells have been linked to poor prognosis and shorter overall survival, indicating its potential as a prognostic marker for breast cancer.